Last reviewed · How we verify
ACH-126,443
At a glance
| Generic name | ACH-126,443 |
|---|---|
| Also known as | beta-L-Fd4C |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants (PHASE2)
- Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation (PHASE1, PHASE2)
- Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A (PHASE2)
- An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment (PHASE2)
- Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B (PHASE2)
- Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection (PHASE2)
- Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs (PHASE2)
- Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACH-126,443 CI brief — competitive landscape report
- ACH-126,443 updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI